GAITHERSBURG, Md., April 04, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Iksung Cho has been named Vice President, Biostatistics.
Mr. Cho joined Novavax in December 2015 as Executive Director, Biostatistics with responsibility for coordinating statistical and statistical programming activities for vaccine candidates in various stages of clinical development. Prior to joining Novavax he was Senior Statistician at PATH, an international nonprofit organization that aims to accelerate innovation across vaccines, drugs, diagnostics, devices and system and service innovations.
Mr. Cho’s experience includes positions of increasing responsibility in biostatistics and data management at Aviron, Merck and MedImmune, where he was Vice President of Global Biostatistics. He earned Master’s degrees in both statistics and applied mathematics from Virginia Polytechnic and State University and completed graduate studies in mathematics.
“Iksung has rapidly become a critical part of our team,” said Gregory M. Glenn, M.D., President, Research and Development. “We expect to leverage his deep experience in biostatistics to evaluate important data readouts from the pivotal Phase 3 Resolve trial of our RSV F Vaccine in older adults and the Phase 2 rollover trial in older adults later this year.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.